» Articles » PMID: 15182893

Naltrexone for Heroin Dependence Treatment in St. Petersburg, Russia

Abstract

Naltrexone may be more effective for treating opioid (heroin) dependence in Russia than in the U.S. because patients are mostly young and living with their parents, who can control medication compliance. In this pilot study we randomized 52 consenting patients who completed detoxification in St. Petersburg to a double blind, 6-month course of biweekly drug counseling and naltrexone, or counseling and placebo naltrexone. Significant differences in retention and relapse favoring naltrexone were seen beginning at 1 month and continuing throughout the study. At the end of 6 months, 12 of the 27 naltrexone patients (44.4%) remained in treatment and had not relapsed as compared to 4 of 25 placebo patients (16%; p<0.05). Since heroin dependence is the main way HIV is being spread in Russia, naltrexone is likely to improve treatment outcome and help reduce the spread of HIV if it can be made more widely available.

Citing Articles

Assessing fragility of statistically significant findings from randomized controlled trials assessing pharmacological therapies for opioid use disorders: a systematic review.

Naji L, Dennis B, Rodrigues M, Bawor M, Hillmer A, Chawar C Trials. 2024; 25(1):286.

PMID: 38678289 PMC: 11055220. DOI: 10.1186/s13063-024-08104-x.


Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials.

Lim J, Farhat I, Douros A, Panagiotoglou D PLoS One. 2022; 17(3):e0266142.

PMID: 35358261 PMC: 8970369. DOI: 10.1371/journal.pone.0266142.


Developmental Considerations for the Use of Naltrexone in Children and Adolescents.

Stancil S, Abdel-Rahman S, Wagner J J Pediatr Pharmacol Ther. 2021; 26(7):675-695.

PMID: 34588931 PMC: 8475793. DOI: 10.5863/1551-6776-26.7.675.


Medication Treatment for Opioid Use Disorders:: A Brief Overview with Comments on Extended Release Naltrexone.

Woody G Dela J Public Health. 2021; 3(4):42-44.

PMID: 34466930 PMC: 8389727. DOI: 10.32481/djph.2017.08.010.


Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report.

Bart G, Saxon A, Fiellin D, McNeely J, Muench J, Shanahan C Addict Sci Clin Pract. 2020; 15(1):4.

PMID: 31948487 PMC: 6966783. DOI: 10.1186/s13722-020-0180-2.